HGH Fragment 176-191 vs Semaglutide

HGH Fragment 176-191: The unmodified C-terminal fragment of growth hormone — the original lipolytic peptide. Typical dose 250-500 mcg. Semaglutide: GLP-1 receptor agonist revolutionizing the treatment of obesity and type 2 diabetes. Typical dose 250-2400 mcg. Both fall under the Weight Management category.

Stacking HGH Fragment 176-191 with Semaglutide is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

HGH Fragment 176-191 is typically dosed: Once daily, morning, on an empty stomach (SubQ) for Fat loss / body recomposition; Twice daily (morning + pre-cardio), fasted for Split-dose protocol for stubborn fat. Semaglutide is typically dosed: Once weekly (SubQ) for Type 2 diabetes (Ozempic); Once weekly (SubQ, after 16-week titration) for Weight management (Wegovy).

HGH Fragment 176-191: Not FDA approved. Distinct from AOD-9604, which holds GRAS status as a food additive. Semaglutide: FDA approved. Ozempic (2017) for type 2 diabetes, Rybelsus (2019) oral for diabetes, Wegovy (2021) for chronic weight management.